Dosimetry of two new interstitial brachytherapy sources

• Authors: Pooneh Saidi , Mahdi Sadeghi
• Languages of publication: EN

Abstracts

EN

With increased demand for low 103Pd (palladium) seed sources, to treat prostate and eye cancers, new sources have been designed and introduced. This article presents the two new palladium brachytherapy sources, IR03-103Pd and IR04-103Pd that have been developed at Nuclear Science and Technology Research Institute. The dosimetry parameters such as the dose rate constant Λ, the radial dose function g(r), and the anisotropy function F(r,θ), around the sources have been characterized using Version 5 Monte Carlo radiation transport code in accordance with the update AAPM Task Group No. 43 report (TG-43U1). The results indicated the dose rate constant of 0.689±0.02 and 0.667±0.02 cGy h-1 U-1 for the IR03-103Pd and IR04-103Pd sources respectively, which are in acceptable agreement with other commercial seeds. The calculated results were compared with published results for those of other source manufacturers. However, they show an acceptable dose distribution, using for clinical applications is pending experimental dosimetry.

Keywords

EN

Monte Carlo calculation; brachytherapy; TG-43U1; MCNP5; 103Pd

• Publisher: Versita
• Journal: Polish Journal of Medical Physics And Engineering
• Year: 2011
• Volume: 17
• Issue: 3
• Pages: 129-141

Dates

published

1 - 1 - 2011

online

20 - 3 - 2012

Contributors

author

Pooneh Saidi

• Department of Nuclear Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran

author

Mahdi Sadeghi

• Agricultural, Medical & Industrial Research School, Nuclear Science and Technology Research Institute, P.O. Box 31485/498, Karaj, Tehran, Iran

References

• Cross section Evaluation Working Group, "ENDF/B-VI Summary documentation (ENDF-201)", Brookhaven National Laboratory Report No. BNL.NCS-17541, 8th ed., National Nuclear Data Center, (December 2000).
• Gearheart DM, Drogin A, Sowards K, Meigooni AS, Ibbott GS. Dosimetric characteristics of a new 125I brachytherapy source. Med Phys. 2000; 27: 2278-2285.
• ---
• Kouwenhoven E, Laarse R, Schaart DR. Variation in interpretation of the AAPM TG-43 geometry factor leads to unclearness in brachytherapy dosimetry. Med Phys 2001; 28: 1965-1966.[Crossref]
• Li Z, Palta JR, Fan JJ. Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source. Med Phys. 2000; 27: 1108-1112.
• Li Z. Monte Carlo calculation of dosimetry parameters of the Urcor Prostaseed 125I source. Med Phys. 2000; 29: 2278-2285.
• Meigooni AS, Bharucha Z, Yoe-Sein M, Sowards K. Dosimetric characteristic of the best double -wall 103Pd brachytherapy source. Med Phys. 2001; 28: 2568-2575.
• Melhus CS, Rivard MJ. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs. Med Phys. 2008; 35: 3364-3371.
• Monte Carlo Team, MCNP-A General Monte Carlo N-Particle Transport Code - Version 5, Los Alamos National Laboratory
• Murali V, Kurup PGG, Mahadev P, Mahalakshmi S. Dosimetric analysis and comparison of IMRT and HDR brachytherapy in treatment of localized prostate cancer. J Med Phys. 2010; 35: 113-119.[Crossref][PubMed]
• Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No.43. American Association of Physicists in Medicine. Med Phys. 1995; 22: 209-234.
• Nath R, Yue N, Shahnazi K, Bongiorni PJ. Measurement of dose-rate constant for 103Pd seeds with air-kerma strength calibration based upon a primary national standard. Med Phys. 2000; 27: 655-658.
• Popescu CC, Wise J, Sowards K, Meigooni AS, Ibbott GS. Dosimetric characteristic of the Pharma Seed model BT-125-I source. Med Phys. 2000; 27: 2174-2181.
• Raisali Gh, Ghonchehnazi MG, Shokrani P, Sadeghi M. Monte Carlo and experimental characterization of the first AMIRS 103Pd brachytherapy. Appl Radiat Isot. 2008: 66: 1856-1860.[WoS]
• Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, Mitch MG, Nath R, Williamson JF. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004; 31: 633-674.[PubMed][Crossref]
• Rivard MJ. Monte Carlo calculation of AAPM Task Group Report No.43 dosimetry parameters for the MED3631-A/M 125I source. Med Phys. 2001; 28: 629-637.
• Sadeghi M, Hosseini SH, Raisali Gh. Experimental measurements and Monte Carlo calculations of dosimetric parameters of the IRA1-103Pd brachytherapy source. Appl Radiat Isot 2008; 66: 1431-1437.
• Sadeghi M, Raisali Gh, Hosseini SH, Shahvar A. Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source. Med Phys. 2008; 35: 1288-1294.
• Saidi P, Sadeghi M, Shirazi A, Tenreiro C. Monte Carlo calculation of dosimetry parameters for the IR08-103Pd brachytherapy source. Med Phys. 2010; 37: 2509-2515.
• Wallace RE, Fan JJ. Dosimetric characterization of a new design 103-palladium brachytherapy source. Med Phys. 1999; 26: 2465-2470.
• Williamson JF. Monte Carlo modeling of the transverse-axis dose distribution of the model 200 103Pd interstitial brachytherapy source. Med Phys. 2000; 27: 643-654.
• Zhang H, Martin D, Chiu-Tsao S, Meigooni A, Thomadsen B. A comprehensive dosimetric between 131Cs and 125I brachytherapy sources for COMS eye plaque implant. Brachytherapy 2010; 9: 362-372.[WoS]

Identifiers

DOI

10.2478/v10013-011-0013-4